Drug Profile
Research programme: diabetes therapy - NPS Pharmaceuticals
Alternative Names: diabetes therapy research programme - NPS Pharmaceuticals; R 467Latest Information Update: 14 May 2007
Price :
$50
*
At a glance
- Originator NPS Pharmaceuticals
- Class
- Mechanism of Action Calcium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 29 Jul 2003 Preclinical trials in Diabetes mellitus in USA (unspecified route)